American Century Companies Inc. Has $16.72 Million Stock Holdings in Revolution Medicines, Inc. $RVMD

American Century Companies Inc. reduced its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD) by 38.7% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 454,572 shares of the company’s stock after selling 287,288 shares during the quarter. American Century Companies Inc. owned approximately 0.24% of Revolution Medicines worth $16,724,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of RVMD. S&CO Inc. increased its holdings in Revolution Medicines by 54.5% in the second quarter. S&CO Inc. now owns 14,171 shares of the company’s stock valued at $521,000 after purchasing an additional 5,000 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in shares of Revolution Medicines in the 2nd quarter valued at about $3,639,000. Harbor Capital Advisors Inc. grew its position in shares of Revolution Medicines by 64.7% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 58,323 shares of the company’s stock valued at $2,146,000 after buying an additional 22,906 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH increased its stake in shares of Revolution Medicines by 7.6% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 71,311 shares of the company’s stock valued at $2,624,000 after buying an additional 5,060 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Revolution Medicines during the first quarter worth about $502,000. Institutional investors own 94.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. HC Wainwright upped their target price on Revolution Medicines from $72.00 to $73.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Royal Bank Of Canada assumed coverage on shares of Revolution Medicines in a research note on Monday, November 3rd. They issued an “outperform” rating and a $77.00 price objective on the stock. National Bankshares set a $80.00 price objective on shares of Revolution Medicines in a research report on Friday, October 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a report on Wednesday, October 8th. Finally, Needham & Company LLC increased their price target on Revolution Medicines from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $78.50.

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, COO Margaret A. Horn sold 4,775 shares of the business’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $45.82, for a total transaction of $218,790.50. Following the sale, the chief operating officer owned 145,900 shares of the company’s stock, valued at $6,685,138. The trade was a 3.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mark A. Goldsmith sold 60,000 shares of the stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $75.08, for a total value of $4,504,800.00. Following the sale, the insider owned 247,863 shares in the company, valued at approximately $18,609,554.04. This represents a 19.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 308,033 shares of company stock worth $17,078,322 over the last quarter. Corporate insiders own 8.20% of the company’s stock.

Revolution Medicines Trading Down 0.6%

Shares of RVMD stock opened at $75.31 on Wednesday. The firm has a market cap of $14.56 billion, a P/E ratio of -14.57 and a beta of 0.96. The company has a 50 day moving average of $58.34 and a 200-day moving average of $45.79. The company has a quick ratio of 8.05, a current ratio of 8.05 and a debt-to-equity ratio of 0.16. Revolution Medicines, Inc. has a 12-month low of $29.17 and a 12-month high of $78.17.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($1.61) earnings per share for the quarter, missing the consensus estimate of ($1.39) by ($0.22). During the same period in the prior year, the company posted ($0.94) earnings per share. Sell-side analysts anticipate that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.